FAQ on Soligenix Inc.'s Heat-Stable Ricin Vaccine Development

What is RiVax(R)?

RiVax(R) is a subunit protein vaccine developed by Soligenix Inc. that incorporates ThermoVax(R) technology to protect against ricin toxin exposure without requiring cold-chain storage.

Why is a heat-stable ricin vaccine important?

A heat-stable vaccine is crucial for biodefense as it eliminates the need for refrigeration, making it easier to distribute and store, especially in areas with limited infrastructure, thereby enhancing public safety against ricin toxin, a potent biothreat.

How does ThermoVax(R) technology work?

ThermoVax(R) technology stabilizes vaccines at elevated temperatures, allowing them to be stored without refrigeration, which is particularly beneficial for vaccines like RiVax(R) that need to be readily available in various conditions.

What stage of development is RiVax(R) in?

RiVax(R) has been shown to be safe in phase 1 studies in humans, with future steps including pivotal animal efficacy studies to further evaluate its effectiveness.

Who is developing the RiVax(R) vaccine?

Soligenix Inc. (NASDAQ: SNGX) is the company behind the development of RiVax(R), leveraging its expertise in vaccine technology and biodefense solutions.

Where can I find more information about Soligenix and RiVax(R)?

More information is available in Soligenix’s newsroom at https://ibn.fm/SNGX and through detailed articles like the one found at InvestorWire.

What makes ricin toxin a significant biothreat?

Ricin toxin is derived from castor beans and is extremely lethal, with a dose as small as a grain of salt being fatal within 48 to 72 hours, making it a serious biothreat that necessitates effective countermeasures like RiVax(R).

What are the implications of RiVax(R) for the vaccine market?

RiVax(R) represents a significant market opportunity in the specialized vaccine sector by addressing a critical public safety need with its innovative, heat-stable formulation, potentially setting a new standard for biodefense vaccines.